Media coverage about Valeritas Holdings (NASDAQ:VLRX) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Valeritas Holdings earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.5360433261661 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news headlines that may have effected Accern’s rankings:
- -$1.65 EPS Expected for Valeritas Holdings, Inc. (VLRX) This Quarter (americanbankingnews.com)
- Active Stocks Falling Down Today – BGG, CETX, CATO, SPTN, VLRX, ICFI, DYNT (fxpips.com)
- Valeritas Holdings (VLRX) Presents At Wedbush PacGrow Healthcare Conference – Slideshow (seekingalpha.com)
- Q3 2017 EPS Estimates for Valeritas Holdings, Inc. Lowered by Wedbush (VLRX) (americanbankingnews.com)
Shares of Valeritas Holdings (NASDAQ:VLRX) traded down 13.5386% on Friday, reaching $3.5795. 56,334 shares of the company traded hands. The company’s market capitalization is $24.49 million. The firm’s 50 day moving average is $5.70 and its 200 day moving average is $11.35. Valeritas Holdings has a one year low of $2.90 and a one year high of $50.00.
Valeritas Holdings (NASDAQ:VLRX) last posted its earnings results on Friday, August 11th. The company reported ($1.83) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.87) by $0.04. The business had revenue of $4.79 million during the quarter, compared to the consensus estimate of $5.11 million. Analysts expect that Valeritas Holdings will post ($8.60) earnings per share for the current fiscal year.
VLRX has been the subject of a number of analyst reports. ValuEngine lowered shares of Valeritas Holdings from a “sell” rating to a “strong sell” rating in a research report on Thursday, May 11th. Wedbush initiated coverage on shares of Valeritas Holdings in a report on Monday, July 10th. They issued an “outperform” rating and a $12.00 price target on the stock. Finally, B. Riley reissued a “buy” rating and issued a $10.00 price target on shares of Valeritas Holdings in a report on Friday, May 12th.
About Valeritas Holdings
Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.
Receive News & Ratings for Valeritas Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.